FDA considering approval of genetically engineered salmon
Cima, G.
Journal of the American Veterinary Medical Association 237(9): 1005-1007
2010
ISSN/ISBN: 0003-1488 PMID: 21090152 Document Number: 638442
Document emailed within 1 workday
Related Documents
Kurihara, H. 2006: Genetically-engineered model animals Nihon Rinsho. Japanese Journal of Clinical Medicine 64(Suppl 5): 267-272Clackson, T.P. 1991: Genetically engineered monoclonal antibodies British Journal of Rheumatology 30(Suppl 2): 36-39
Koda, T.; Togashi, Y.; Nishimura, T. 2002: Genetically engineered mice and its application to bioindustry Hokkaido Journal of Medical Science 77(2): 151-156
Colcher, D.; Pavlinkova, G.; Beresford, G.; Booth, B.J.; Choudhury, A.; Batra, S.K. 1998: Pharmacokinetics and biodistribution of genetically-engineered antibodies Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology 42(4): 225-241
Doetschman, T. 1999: Interpretation of phenotype in genetically engineered mice Laboratory Animal Science 49(2): 137-143
Gorlach, K. 1994: Problems in the introduction of genetically engineered microorganisms into the environment Acta Microbiologica Polonica 43(2): 121-131
Parren, P.W. 1992: Preparation of genetically engineered monoclonal antibodies for human immunotherapy Human Antibodies and Hybridomas 3(3): 137-145
Iwamoto, T.; Kita, S.; Shigekawa, M. 2002: Functional analysis of Na+/Ca2+ exchanger using novel drugs and genetically engineered mice Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 120(1): 91p-93p
Yoshida, S.; Shimada, Y.; Watanabe, H. 2007: Novel approach toward infectious diseases--combating malaria by using genetically engineered mosquitoes Nihon Rinsho. Japanese Journal of Clinical Medicine 65(9): 1715-1726
Sandstrom, P.A.; Folks, T.M. 2001: Facilitated detection of adventitious agents using genetically engineered cell lines Developments in Biologicals 106: 375-378; Discussion: 379-380
Rockman, H.A.; Koch, W.J.; Lefkowitz, R.J. 1997: Cardiac function in genetically engineered mice with altered adrenergic receptor signaling American Journal of Physiology 272(4 Pt 2): H1553-H1559
Tartaglia, J.; Cox, W.I.; Pincus, S.; Paoletti, E. 1994: Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC Developments in Biological Standardization 82: 125-129
Markert, J.M.; Parker, J.N.; Gillespie, G.Y.; Whitley, R.J. 2001: Genetically engineered human herpes simplex virus in the treatment of brain tumours Herpes: the Journal of the Ihmf 8(1): 17-22
Kang, P.; Shen, X.M.; Yu, H.M. 1995: Study on the efficacy of genetically engineered vaccines against hepatitis B for interruption of perinatal transmission Zhonghua Hu Li Za Zhi 30(7): 390-392
Zitvogel, L.; Tahara, H.; Robbins, P.D.; Storkus, W.J.; Clarke, M.R.; Nalesnik, M.A.; Lotze, M.T. 1995: Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts Journal of Immunology 155(3): 1393-1403
Ivankin, A.N.; Mitaleva, S.I.; Nekliudov, A.D. 1998: Biosynthesis and isolation of a recombinant protein for producing genetically-engineered human proinsulin Prikladnaia Biokhimiia i Mikrobiologiia 34(3): 293-299
Daunert, S.; Barrett, G.; Feliciano, J.S.; Shetty, R.S.; Shrestha, S.; Smith-Spencer, W. 2000: Genetically engineered whole-cell sensing systems: coupling biological recognition with reporter genes Chemical Reviews 100(7): 2705-2738
Saxon, A.; Zhu, D.; Zhang, K.; Chan, L.A.; Kepley, C.L. 2006: Recent advances in the use of genetically engineered negative signaling molecules to treat allergic diseases Arbeiten aus dem Paul-Ehrlich-Institut Zu Frankfurt A.M 2006(95): 223-31; Discussion 231-3
Moiseev, S.V.; Novikov, P.I.; Semenkova, E.N.; Strizhakov, L.A.; Gulyaev, S.V.; Yanushkevich, T.N.; Nikiforova, N.V.; Meshkov, A.D.; Panasyuk, V.V.; Sokorin, Y.D.; Taranova, M.V.; Parfenova, S.A.; Dubrovskaya, L.V.; Zhabina, E.S.; Kuznetsova, E.I.; Lopatina, I.A.; Bulanov, N.M.; Mukhin, N.A. 2013: Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases Terapevticheskii Arkhiv 85(5): 37-43
Andreansky, S.; Soroceanu, L.; Flotte, E.R.; Chou, J.; Markert, J.M.; Gillespie, G.Y.; Roizman, B.; Whitley, R.J. 1997: Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors Cancer Research 57(8): 1502-1509